Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ambion Inc.

www.ambion.com

Latest From Ambion Inc.

The A-List: 2006's Trend-Shaping Series A Financings

2006's most intriguing Series As reflect VCs' continued emphasis on risk reduction through reprofiling in biotech, and big gains in funding for diagnostics and device start-ups.
BioPharmaceutical Medical Device

GeneXP Biosciences Inc.

The managers of GeneXP Biosciences think the global views of gene expression afforded by Affymetrix's microarray chips have their limitations--too much information. GeneXP aims to serve researchers who are ready to focus on specific gene sets. It will sell companies the tools and equipment they need to do high-throughput gene expression studies--or do the work for them.
BioPharmaceutical Medical Device

Recent Dealmaking (02/2004)

Summarizing the month in European dealmaking.

Cenix BioScience GmbH

Cenix is equipped to do high-throughput, genome-scale RNAi screening. The firm believes that its infrastructure and expertise will allow it to help Big pharma and biotech partners sort through masses of targets to find those with biological relevance. Management believes its methodology can also contribute to drug development--RNAi could, for instance, act as a modifier in screening assays, to see whether this additional means of silencing a gene could improve a drug candidate's activity.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ambion Inc.
  • Senior Management
  • Matt Winkler, CEO
    John Dahler, CFO
    Peter Donahue , Dir., Bus. Dev.
    Bruce W Leander, Pres.
  • Contact Info
  • Ambion Inc.
    Phone: (512) 651-0200
    2130 Woodward
    Austin, TX 78744-1832
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register